BsAb vs CAR-T efficacy
| Class . | Agent . | Trial . | N . | Demographics . | Follow-up (months) . | ORR (%) . | CRR (%) . | Survival outcomes . | Duration of response . | |
|---|---|---|---|---|---|---|---|---|---|---|
| POD24 (%) . | Refractory to prior therapy . | |||||||||
| Bispecific antibody | Mosunetuzumab | NCT02500407 (GO29781) | 90 | 52 | 69 | 37 | 78 | 60 | 36-mo PFS: 43% | 30-mo DOCR: 72% |
| Bispecific antibody | Epcoritamab | NCT03625037 (EPCORE NHL-1) | 128a | 42 | 69 | 17 | 82 | 63 | Median PFS: 15.4 mo | 18-mo DOCR: 72% |
| Bispecific antibody | Odronextamab | NCT02290951 (ELM-1) | 128b | 49 | 72 | 27 | 81 | 73 | 24-mo PFS: 45% | 24-mo DOCR: 48% |
| CAR T cell | Axicabtagene-ciloleucel | NCT03105336 (ZUMA-5) | 127 | 55 | 69 | 42 | 94 | 79 | 36-mo PFS: 54% | 36-mo DOCR: 62% |
| CAR T cell | Tisagenlecleucel | NCT03568461 (ELARA) | 97 | 63 | 78 | 29 | 86 | 68 | 24-mo PFS: 57% | 24-mo DOCR: 78% |
| CAR T cell | Lisocabtagene-maraleucel | NCT04245839 (TRANSCEND FL) | 107c | 43 | 38 | 19 | 97 | 94 | 12-mo PFS: 81% | 12-mo DOCR: 82% |
| Class . | Agent . | Trial . | N . | Demographics . | Follow-up (months) . | ORR (%) . | CRR (%) . | Survival outcomes . | Duration of response . | |
|---|---|---|---|---|---|---|---|---|---|---|
| POD24 (%) . | Refractory to prior therapy . | |||||||||
| Bispecific antibody | Mosunetuzumab | NCT02500407 (GO29781) | 90 | 52 | 69 | 37 | 78 | 60 | 36-mo PFS: 43% | 30-mo DOCR: 72% |
| Bispecific antibody | Epcoritamab | NCT03625037 (EPCORE NHL-1) | 128a | 42 | 69 | 17 | 82 | 63 | Median PFS: 15.4 mo | 18-mo DOCR: 72% |
| Bispecific antibody | Odronextamab | NCT02290951 (ELM-1) | 128b | 49 | 72 | 27 | 81 | 73 | 24-mo PFS: 45% | 24-mo DOCR: 48% |
| CAR T cell | Axicabtagene-ciloleucel | NCT03105336 (ZUMA-5) | 127 | 55 | 69 | 42 | 94 | 79 | 36-mo PFS: 54% | 36-mo DOCR: 62% |
| CAR T cell | Tisagenlecleucel | NCT03568461 (ELARA) | 97 | 63 | 78 | 29 | 86 | 68 | 24-mo PFS: 57% | 24-mo DOCR: 78% |
| CAR T cell | Lisocabtagene-maraleucel | NCT04245839 (TRANSCEND FL) | 107c | 43 | 38 | 19 | 97 | 94 | 12-mo PFS: 81% | 12-mo DOCR: 82% |
EPCORE NHL-1 FL study: N = 128 for efficacy and safety except for CRS and ICANS (N = 86 optimization cohort).
ELM-2 study: N = 128 for efficacy and safety except for CRS and ICANS (N = 60 optimization cohort).
TRANSCEND FL study: third-line or beyond FL for efficacy (N = 107), second-line or beyond FL for safety (N = 130).
CRR, complete response rate.